90 results - The Consciousness Library

Safety Profile of Psilocybin for Cocaine Use Disorder (opens ClinicalTrials.gov in a new tab)

Suspended Early Phase 1 10 participants University of California, Los Angeles

Cocaine Use Disorder

Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Early Phase 1 60 participants Roswell Park Cancer Institute

Cannabis Dependence

MDMA-assisted Therapy for Fibromyalgia (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 20 participants Spaulding Rehabilitation Hospital

Fibromyalgia

Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) (opens ClinicalTrials.gov in a new tab)

Suspended Early Phase 1 5 participants University of Wisconsin, Madison

Posttraumatic Stress Disorder

Psilocybin Administration With 5-HT1a Blockade (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 18 participants Johns Hopkins University

Psychedelic Effects in Healthy Volunteers

Psilocybin Microdosing on Cognition, Mood and Quality of Life (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Early Phase 1 20 participants Yale University

Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Early Phase 1 10 participants NYU Langone Health

IBS - Irritable Bowel Syndrome

Research Investigating Drug Effects-2 (RiDE-2) (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Early Phase 1 144 participants University of Illinois at Chicago

Cannabis Use, Substance Use Disorder (SUD), Healthy

Psilocybin as a Treatment for Chronic Pain in Smokers (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 10 participants Yale University

Smokers With Chronic Pain

Ketamine in Severe Traumatic Brain Injury (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 10 participants University of Texas Southwestern Medical Center

Traumatic Brain Injury, Traumatic Encephalopathy

Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin. (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 100 participants Pontifícia Universidade Católica do Rio de Janeiro

Healthy Adults

Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 10 participants University of Pennsylvania

Major Depressive Disorder (MDD)

Psilocybin for Prolonged Grief Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 12 participants University of Virginia

Prolonged Grief Disorder

Sleep, Dreaming, and Virtual Reality for Mental Health (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 70 participants Northwestern University

Anxiety

Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 220 participants Min Su

Esketamine, ECT, Depression, Adolescent

Feasibility of a Mental-Health Intervention Based on Contemplative Sleep Practices (opens ClinicalTrials.gov in a new tab)

Completed Early Phase 1 25 participants Northwestern University

Anxiety

PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 30 participants Imperial College London

Self Harm

Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 13 participants Tel-Aviv Sourasky Medical Center

Post-Traumatic Stress Disorder, PTSD

Drug Effects on Mood and Behavior - Expectancy (opens ClinicalTrials.gov in a new tab)

Completed Early Phase 1 42 participants University of Chicago

LSD

Mood Effects of Serotonin Agonists: Depression (opens ClinicalTrials.gov in a new tab)

Completed Early Phase 1 41 participants University of Chicago

LSD, Major Depressive Disorder, Depression

Mechanistic Studies of Psilocybin in Headache Disorders (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 50 participants Yale University

Migraine

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 24 participants Johns Hopkins University

Amyotrophic Lateral Sclerosis

Psilocybin for Methamphetamine Addiction (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 20 participants Kevin Murnane

Methamphetamine Use Disorder

Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Early Phase 1 100 participants University of Zurich

Depressive Symptoms Mild to Moderate in Severity, Anxiety, Quality of Life (QOL), Caregiver Burden

Personalized DBS Targeting for Treating Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Early Phase 1 5 participants Second Affiliated Hospital, Zhejiang University, School of Medicine

Treatment-resistant Depression (TRD)